GILD phase III program in GT2/3 has 3 patients populations: Naïve in FISSION trial Interferon unwilling/intolerant/ineligible in POSITRON Treatment Experienced in FUSION
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.